SHR-1701 + Rivoceranib (± SHR-2554) in Advanced GC After First-Line Immunotherapy Failure

To investigate the efficacy of SHR-1701 combined with Rivoceranib, with or without SHR-2554, in patients with gastric or gastroesophageal junction adenocarcinoma who have progressed on or were intolerant to first-line immunotherapy-containing treatment

Trial Details

NCT ID
NCT07311408
Phase
PHASE2
Sponsor
Jingdong Zhang
Status
RECRUITING
Cancer Type
Gastric Cancer
Interventions
  • SHR-1701+Rivoceranib + SHR-2554
  • SHR-1701 + Rivoceranib
Locations (sample)
  • Shenyang, Liaoning, China|41.79222,123.43278

Key Eligibility Criteria

  • Age ≥ 18 years, male or female.
  • Histologically or pathologically confirmed diagnosis of gastric or gastroesophageal junction adenocarcinoma.
  • Disease progression on or intolerance to a prior treatment regimen that contained an immune checkpoint inhibitor (ICI).
  • HER2-negative expression.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Gastric Cancer Trials on Trialify →